Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
The Autism Impact Fund (AIF) is a venture capital firm founded in 2020 and based in the United States. It focuses on healthcare technology and innovation, specifically in behavioral health, mental health, and autism. AIF was created to tackle the fragmented systems families encounter when seeking support for autism and related conditions.
AIF invests in early- and growth-stage companies within the healthcare sector, particularly those addressing behavioral health, mental health, and complex chronic conditions. The firm targets investments in diagnostics, digital health, therapeutics, and care delivery, emphasizing the need to resolve gaps and inefficiencies in these markets.
AIF's portfolio features notable companies such as Auticon, which employs neurodiverse adults in ICT roles; BioROSA, developing a blood test for early autism detection; and Bluebird Kids Health, enhancing care access for children on Medicaid and CHIP. Other investments include Camber, a software solution for behavioral health clinicians; Cortica, a comprehensive care provider; Eleplan, a caregiving platform; Floreo, a VR platform for social skills training; and Healios (Meliora Health), a telehealth service for autism and ADHD care.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.